Staying local, thinking global

Kiadis Pharma B.V. hopes to double up the local hero effect with its planned IPO on both Euronext Amsterdam and Euronext Brussels while still attracting about half of its new investors from the U.S.

The primary listing will be on Euronext Amsterdam, the city where Kiadis is headquartered, and home to the biotech's largest shareholder, LSP. Kiadis also wanted to list on the Brussels exchange, because Belgium is the country where most European patients have been treated with the company's ATIR101 T cell-depleted donor lymphocytes in clinical trials. Kiadis investor Quest for Growth is also based there...